Antimicrobial Peptides Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019–2029, Segmented By Product (Plant, Bacterial, Animal, Insect); By Ailments (Pneumonia, Hepatitis, Bacterial infections, HIV); By Distribution Channel

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,850	200 Pages	BlueWeave Consulting	November, 2023	BLWC18529118

Best Price Guarantee
Price	from $4,850
Length	200 Pages
Publisher	BlueWeave Consulting
Published Date	November, 2023
SKU	BLWC18529118

Acrylonitrile Butadiene Styrene (ABS) Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019–2029, Segmented By Type (Opaque, Transparent, Colored); By Process Type (Injection Blow Molding, Extrusion Blow Molding, Injection Stretch Blow Molding); By Application (Automotive & Transportation, Construction, Electronics, Consumer Goods & Appliances); By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

Global Antimicrobial Peptides Market Size Set to Grow at Steady CAGR of 5.54% Reaching USD 7.56 Billion by 2029

Global antimicrobial peptides market is flourishing due to an increasing demand for alternative antibiotics due to antimicrobial resistance, the rising prevalence of infectious diseases, expanding applications in pharmaceuticals and biotechnology, and advancements in peptide synthesis technologies.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the global antimicrobial peptides market size at USD 5.47 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects the global antimicrobial peptides market size to grow at a CAGR of 5.54% reaching a value of USD 7.56 billion by 2029. The rising incidence of drug-resistant illnesses spurred the desire for alternative therapeutics, such as antimicrobial peptides, which exhibit promising efficacy against resistant bacteria and are one of the major reasons driving the growth of the global antimicrobial peptides market. Also, improvements in peptide manufacturing and synthesis methods lowered production costs and increased accessibility. Increasing research and development spending also resulted in the creation of new peptide-based medicines, which expanded the market. The market expansion is further fueled by growing knowledge of the advantages of antimicrobial peptides in a range of medical and non-medical uses, including food preservation and agriculture.

Antimicrobial Peptides – Overview

Antimicrobial peptides (AMPs) are naturally occurring tiny compounds present in a wide range of organisms, including people, plants, and animals. They are essential in innate immunity, as they protect against microbial infections. The antimicrobial activity of AMPs is broad-spectrum, targeting bacteria, fungi, viruses, and even some parasites. Their distinct method of action involves breaking microbial membranes, resulting in cell death, and they are resistant to resistance formation. AMPs have sparked attention in the fight against antibiotic-resistant bacteria and other infectious disorders due to their potential therapeutic applications. However, there are still issues in optimizing their stability and bioavailability for therapeutic usage, necessitating continuous study.

Impact of COVID-19 on Global Antimicrobial Peptides Market

The COVID-19 pandemic significantly impacted the global antimicrobial peptides market, causing a dynamic shift in demand and supply chains. With heightened awareness of infection prevention and treatment, the market witnessed accelerated research and development, driving innovation and adoption of antimicrobial peptides as potential therapeutic agents against the virus. However, disruptions in manufacturing, logistical challenges, and resource reallocation to combat the pandemic resulted in temporary setbacks for some market players. Despite these challenges, the pandemic underscored the importance of antimicrobial peptides, prompting increased investments and collaborations for developing robust antimicrobial solutions, and fostering long-term growth prospects for the market.

Global Antimicrobial Peptides Market – By Ailments

By ailments, the global antimicrobial peptides market is divided into Pneumonia, Hepatitis, Bacterial infections, and HIV segments. These segments represent distinct areas of application for antimicrobial peptides, which are naturally occurring molecules with potent antimicrobial properties. The market is driven by the increasing prevalence of infectious diseases and the growing demand for effective treatment options. Each segment presents unique challenges and opportunities, prompting pharmaceutical companies and researchers to explore and develop innovative peptide-based therapies to combat these specific diseases. This segmentation enables targeted approaches and tailored solutions to address the diverse healthcare needs associated with these infectious conditions.

Competitive Landscape

Global antimicrobial peptides market is fiercely competitive. Major companies in the market include Eli Lilly and Company, Pfizer Inc., GSK Group of Companies (U.S.), Novartis AG, EnBiotix Inc., Johnson & Johnson Private Limited, Merck & Co., Inc., Alexion Pharmaceuticals, Inc., Melinta Therapeutics, LLC, Vertex Pharmaceuticals Incorporated, AnaSpec, AMP Biotech, Phoenix Biotechnology Inc., Novabiotics, and Ontores Biotechnologies Inc. These companies use various strategies, including increasing investments in their R&D activities, mergers, and acquisitions, joint ventures, collaborations, licensing agreements, and new product and service releases to further strengthen their position in global antimicrobial peptides market.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Antimicrobial Peptides Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Antimicrobial Peptides Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

1. Research Framework: 1.1. Research Objective; 1.2. Product Overview; 1.3. Market Segmentation
2. Executive Summary
3. Global Antimicrobial Peptides Market Insights: 3.1. Industry Value Chain Analysis; 3.2. DROC Analysis; 3.2.1. Growth Drivers; 3.2.1.1. Rise in infectious diseases; 3.2.1.2. Increasing usage of antimicrobial peptides as therapeutic agents; 3.2.1.3. Rising incidence of antimicrobial resistance; 3.2.2. Restraints; 3.2.2.1. High development costs; 3.2.2.2. Stability and formulation issues:; 3.2.3. Opportunities; 3.2.3.1. Technological advancements; 3.2.3.2. Rising incidence of central line-associated bloodstream infections; 3.2.4. Challenges; 3.2.4.1. Regulatory challenges; 3.2.4.2. Limited market awareness; 3.3. Technological Advancements/Recent Developments; 3.4. Regulatory Framework; 3.5. Porter’s Five Forces Analysis; 3.5.1. Bargaining Power of Suppliers; 3.5.2. Bargaining Power of Buyers; 3.5.3. Threat of New Entrants; 3.5.4. Threat of Substitutes; 3.5.5. Intensity of Rivalry
4. Global Antimicrobial Peptides Market Overview: 4.1. Market Size & Forecast, 2019–2029; 4.1.1. By Value (USD Million); 4.2. Market Share & Forecast; 4.2.1. By Product; 4.2.1.1. Plant; 4.2.1.2. Bacterial; 4.2.1.3. Animal; 4.2.1.4. Insect; 4.2.2. By Ailments; 4.2.2.1.1. Pneumonia; 4.2.2.1.2. Hepatitis; 4.2.2.1.3. Bacterial infections; 4.2.2.1.4. HIV; 4.2.3. By Distribution Channel; 4.2.3.1.1. Hospital; 4.2.3.1.2. Research Institutes; 4.2.3.1.3. Specialty Clinic; 4.2.3.1.4. Pharmacies; 4.2.4. By Route of Administration; 4.2.4.1. Topical; 4.2.4.2. Subcutaneous; 4.2.4.3. Intravenous; 4.2.5. By End Use; 4.2.5.1. Pharma and Healthcare; 4.2.5.2. Agriculture Industry; 4.2.5.3. Biological Engineering; 4.2.6. By Region; 4.2.6.1. North America; 4.2.6.2. Europe; 4.2.6.3. Asia Pacific (APAC); 4.2.6.4. Latin America (LATAM); 4.2.6.5. Middle East and Africa (MEA)
5. North America Antimicrobial Peptides Market: 5.1. Market Size & Forecast, 2019–2029; 5.1.1. By Value (USD Million); 5.2. Market Share & Forecast; 5.2.1. By Product; 5.2.2. By Ailments; 5.2.3. By Distribution Channel; 5.2.4. By Route of Administration; 5.2.5. By End Use; 5.2.6. By Country; 5.2.6.1. United States; 5.2.6.1.1. By Product; 5.2.6.1.2. By Ailments; 5.2.6.1.3. By Distribution Channel; 5.2.6.1.4. By Route of Administration; 5.2.6.1.5. By End Use; 5.2.6.2. Canada; 5.2.6.2.1. By Product; 5.2.6.2.2. By Ailments; 5.2.6.2.3. By Distribution Channel; 5.2.6.2.4. By Route of Administration; 5.2.6.2.5. By End Use
6. Europe Antimicrobial Peptides Market: 6.1. Market Size & Forecast, 2019–2029; 6.1.1. By Value (USD Million); 6.2. Market Share & Forecast; 6.2.1. By Product; 6.2.2. By Ailments; 6.2.3. By Distribution Channel; 6.2.4. By Route of Administration; 6.2.5. By End Use; 6.2.6. By Country; 6.2.6.1. Germany; 6.2.6.1.1. By Product; 6.2.6.1.2. By Ailments; 6.2.6.1.3. By Distribution Channel; 6.2.6.1.4. By Route of Administration; 6.2.6.1.5. By End Use; 6.2.6.2. United Kingdom; 6.2.6.2.1. By Product; 6.2.6.2.2. By Ailments; 6.2.6.2.3. By Distribution Channel; 6.2.6.2.4. By Route of Administration; 6.2.6.2.5. By End Use; 6.2.6.3. Italy; 6.2.6.3.1. By Product; 6.2.6.3.2. By Ailments; 6.2.6.3.3. By Distribution Channel; 6.2.6.3.4. By Route of Administration; 6.2.6.3.5. By End Use; 6.2.6.4. France; 6.2.6.4.1. By Product; 6.2.6.4.2. By Ailments; 6.2.6.4.3. By Distribution Channel; 6.2.6.4.4. By Route of Administration; 6.2.6.4.5. By End Use; 6.2.6.5. Spain; 6.2.6.5.1. By Product; 6.2.6.5.2. By Ailments; 6.2.6.5.3. By Distribution Channel; 6.2.6.5.4. By Route of Administration; 6.2.6.5.5. By End Use; 6.2.6.6. Belgium; 6.2.6.6.1. By Product; 6.2.6.6.2. By Ailments; 6.2.6.6.3. By Distribution Channel; 6.2.6.6.4. By Route of Administration; 6.2.6.6.5. By End Use; 6.2.6.7. Russia; 6.2.6.7.1. By Product; 6.2.6.7.2. By Ailments; 6.2.6.7.3. By Distribution Channel; 6.2.6.7.4. By Route of Administration; 6.2.6.7.5. By End Use; 6.2.6.8. The Netherlands; 6.2.6.8.1. By Product; 6.2.6.8.2. By Ailments; 6.2.6.8.3. By Distribution Channel; 6.2.6.8.4. By Route of Administration; 6.2.6.8.5. By End Use; 6.2.6.9. Rest of Europe; 6.2.6.9.1. By Product; 6.2.6.9.2. By Ailments; 6.2.6.9.3. By Distribution Channel; 6.2.6.9.4. By Route of Administration; 6.2.6.9.5. By End Use
7. Asia Pacific Antimicrobial Peptides Market: 7.1. Market Size & Forecast, 2019–2029; 7.1.1. By Value (USD Million); 7.2. Market Share & Forecast; 7.2.1. By Product; 7.2.2. By Ailments; 7.2.3. By Distribution Channel; 7.2.4. By Route of Administration; 7.2.5. By End Use; 7.2.6. By Country; 7.2.6.1. China; 7.2.6.1.1. By Product; 7.2.6.1.2. By Ailments; 7.2.6.1.3. By Distribution Channel; 7.2.6.1.4. By Route of Administration; 7.2.6.1.5. By End Use; 7.2.6.2. India; 7.2.6.2.1. By Product; 7.2.6.2.2. By Ailments; 7.2.6.2.3. By Distribution Channel; 7.2.6.2.4. By Route of Administration; 7.2.6.2.5. By End Use; 7.2.6.3. Japan; 7.2.6.3.1. By Product; 7.2.6.3.2. By Ailments; 7.2.6.3.3. By Distribution Channel; 7.2.6.3.4. By Route of Administration; 7.2.6.3.5. By End Use; 7.2.6.4. South Korea; 7.2.6.4.1. By Product; 7.2.6.4.2. By Ailments; 7.2.6.4.3. By Distribution Channel; 7.2.6.4.4. By Route of Administration; 7.2.6.4.5. By End Use; 7.2.6.5. Australia & New Zealand; 7.2.6.5.1. By Product; 7.2.6.5.2. By Ailments; 7.2.6.5.3. By Distribution Channel; 7.2.6.5.4. By Route of Administration; 7.2.6.5.5. By End Use; 7.2.6.6. Indonesia; 7.2.6.6.1. By Product; 7.2.6.6.2. By Ailments; 7.2.6.6.3. By Distribution Channel; 7.2.6.6.4. By Route of Administration; 7.2.6.6.5. By End Use; 7.2.6.7. Malaysia; 7.2.6.7.1. By Product; 7.2.6.7.2. By Ailments; 7.2.6.7.3. By Distribution Channel; 7.2.6.7.4. By Route of Administration; 7.2.6.7.5. By End Use; 7.2.6.8. Singapore; 7.2.6.8.1. By Product; 7.2.6.8.2. By Ailments; 7.2.6.8.3. By Distribution Channel; 7.2.6.8.4. By Route of Administration; 7.2.6.8.5. By End Use; 7.2.6.9. Vietnam; 7.2.6.9.1. By Product; 7.2.6.9.2. By Ailments; 7.2.6.9.3. By Distribution Channel; 7.2.6.9.4. By Route of Administration; 7.2.6.9.5. By End Use; 7.2.6.10. Rest of APAC; 7.2.6.10.1. By Product; 7.2.6.10.2. By Ailments; 7.2.6.10.3. By Distribution Channel; 7.2.6.10.4. By Route of Administration; 7.2.6.10.5. By End Use
8. Latin America Antimicrobial Peptides Market: 8.1. Market Size & Forecast, 2019–2029; 8.1.1. By Value (USD Million); 8.2. Market Share & Forecast; 8.2.1. By Product; 8.2.2. By Ailments; 8.2.3. By Distribution Channel; 8.2.4. By Route of Administration; 8.2.5. By End Use; 8.2.6. By Country; 8.2.6.1. Brazil; 8.2.6.1.1. By Product; 8.2.6.1.2. By Ailments; 8.2.6.1.3. By Distribution Channel; 8.2.6.1.4. By Route of Administration; 8.2.6.1.5. By End Use; 8.2.6.2. Mexico; 8.2.6.2.1. By Product; 8.2.6.2.2. By Ailments; 8.2.6.2.3. By Distribution Channel; 8.2.6.2.4. By Route of Administration; 8.2.6.2.5. By End Use; 8.2.6.3. Argentina; 8.2.6.3.1. By Product; 8.2.6.3.2. By Ailments; 8.2.6.3.3. By Distribution Channel; 8.2.6.3.4. By Route of Administration; 8.2.6.3.5. By End Use; 8.2.6.4. Peru; 8.2.6.4.1. By Product; 8.2.6.4.2. By Ailments; 8.2.6.4.3. By Distribution Channel; 8.2.6.4.4. By Route of Administration; 8.2.6.4.5. By End Use; 8.2.6.5. Rest of LATAM; 8.2.6.5.1. By Product; 8.2.6.5.2. By Ailments; 8.2.6.5.3. By Distribution Channel; 8.2.6.5.4. By Route of Administration; 8.2.6.5.5. By End Use
9. Middle East and Africa Antimicrobial Peptides Market: 9.1. Market Size & Forecast, 2019–2029; 9.1.1. By Value (USD Million); 9.2. Market Share & Forecast; 9.2.1. By Product; 9.2.2. By Ailments; 9.2.3. By Distribution Channel; 9.2.4. By Route of Administration; 9.2.5. By End Use; 9.2.6. By Country; 9.2.6.1. Saudi Arabia; 9.2.6.1.1. By Product; 9.2.6.1.2. By Ailments; 9.2.6.1.3. By Distribution Channel; 9.2.6.1.4. By Route of Administration; 9.2.6.1.5. By End Use; 9.2.6.2. UAE; 9.2.6.2.1. By Product; 9.2.6.2.2. By Ailments; 9.2.6.2.3. By Distribution Channel; 9.2.6.2.4. By Route of Administration; 9.2.6.2.5. By End Use; 9.2.6.3. Qatar; 9.2.6.3.1. By Product; 9.2.6.3.2. By Ailments; 9.2.6.3.3. By Distribution Channel; 9.2.6.3.4. By Route of Administration; 9.2.6.3.5. By End Use; 9.2.6.4. Kuwait; 9.2.6.4.1. By Product; 9.2.6.4.2. By Ailments; 9.2.6.4.3. By Distribution Channel; 9.2.6.4.4. By Route of Administration; 9.2.6.4.5. By End Use; 9.2.6.5. South Africa; 9.2.6.5.1. By Product; 9.2.6.5.2. By Ailments; 9.2.6.5.3. By Distribution Channel; 9.2.6.5.4. By Route of Administration; 9.2.6.5.5. By End Use; 9.2.6.6. Nigeria; 9.2.6.6.1. By Product; 9.2.6.6.2. By Ailments; 9.2.6.6.3. By Distribution Channel; 9.2.6.6.4. By Route of Administration; 9.2.6.6.5. By End Use; 9.2.6.7. Algeria; 9.2.6.7.1. By Product; 9.2.6.7.2. By Ailments; 9.2.6.7.3. By Distribution Channel; 9.2.6.7.4. By Route of Administration; 9.2.6.7.5. By End Use; 9.2.6.8. Rest of MEA; 9.2.6.8.1. By Product; 9.2.6.8.2. By Ailments; 9.2.6.8.3. By Distribution Channel; 9.2.6.8.4. By Route of Administration; 9.2.6.8.5. By End Use
10. Competitive Landscape: 10.1. List of Key Players and Their Offerings; 10.2. Global Antimicrobial Peptides Company Market Share Analysis, 2022; 10.3. Competitive Benchmarking, By Operating Parameters; 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)
11. Impact of COVID-19 on Global Antimicrobial Peptides Market
12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis): 12.1. Eli Lilly and Company; 12.2. Pfizer Inc.; 12.3. GSK Group of Companies (U.S); 12.4. Novartis AG; 12.5. EnBiotix Inc.; 12.6. Johnson & Johnson Private Limited; 12.7. Merck & Co., Inc.; 12.8. Alexion Pharmaceuticals, Inc.; 12.9. Melinta Therapeutics, LLC; 12.10. Vertex Pharmaceuticals Incorporated; 12.11. AnaSpec; 12.12. AMP Biotech; 12.13. Phoenix Biotechnology Inc.; 12.14. Novabiotics; 12.15. Ontores Biotechnologies Inc.; 12.16. Other Prominent Players
13. Key Strategic Recommendations
14. Research Methodology: 14.1. Qualitative Research; 14.1.1. Primary & Secondary Research; 14.2. Quantitative Research; 14.3. Market Breakdown & Data Triangulation; 14.3.1. Secondary Research; 14.3.2. Primary Research; 14.4. Breakdown of Primary Research Respondents, By Region; 14.5. Assumptions & Limitations